SAPIEN 3 Ultra RESILIA valve: 1-year real-world outcomes with significant mortality benefits for patients - European Medical Journal

This content is intended for healthcare professionals from Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden

Continue

SAPIEN 3 Ultra RESILIA valve: 1-year real-world outcomes with significant mortality benefits for patients

Interventional Cardiology
Download PDF

The publication of this infographic was sponsored by Edwards Lifesciences.

This content is intended for healthcare professionals. EMJ has published this infographic on behalf of Edwards Lifesciences and has had no input into its creation.

SAPIEN 3 Ultra RESILIA valve shows significant 1-year benefits, including lower all-cause mortality (driven by lower PVL),  stroke, and bleeding compared to earlier models. Strong indications for lifetime management, including younger, low-risk patients.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.